2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

Portefølje Naturvitenskap og teknologi ikon

Forskningssystemet

Portefølje Humaniora og samfunnsvitenskap ikon

Banebrytende forskning

Portefølje Samisk ikon

Samisk samfunn og kultur

Portefølje Demokrati, styring og fornyelse ikon

Demokrati og global utvikling

Portefølje Velferd, kultur og samfunn ikon

Velferd og utdanning

Portefølje Helse ikon

Helse

Portefølje Klima- og polarforskning ikon

Klima og miljø

Portefølje Landbasert mat, miljø og bioressurser ikon

Mat og bioressurser

Portefølje Energi, transport og lavutslipp ikon

Energi og transport

Portefølje Muliggjørende teknologier ikon

Muliggjørende teknologier

Portefølje Industri og tjenestenæringer ikon

Innovasjon

LTP2 Klima, miljø og miljøvennlig energi ikon

Klima, miljø og energi

LTP2 Samfunnssikkerhet og samhørighet ikon

Samfunnstryggleik og beredskap

LTP2 Fornyelse i offentlig sektor ikon

Velferdstjenester

Forsidebilde

Marin ikon

Petroleum og mineraler

LTP Hav ikon

Hav og kyst

LTP2 Muliggjørende og industrielle teknologier ikon

Mogleggjerande industrielle teknologiar

Tillit og fellesskap

LTP2 Utvikle fagmiljøer av fremragende kvalitet

Høg kvalitet og tilgjengeleg

LTP2 Styrket konkurransekraft og innovasjonsevne ikon

Sterkare konkurransekraft og innovasjonsevne

LTP3 Helse

Et innovativt næringsliv ikon

Styrket konkurransekraft og innovasjonsevne

Portefolje Petroleum Ikon

Portefølje Hav ikon

Portefølje Utdanning og kompetanse ikon

Portefølje Global utvikling og internasjonale relasjoner ikon

Portefølje Livsvitenskap ikon

Forsidebilde optimalisert

project-bank-technical

Muliggjørende teknologier bakgrunn

Marin bakgrunnsbilde

Statistikk

Prosjektbanken presenterer statistikk og informasjon om prosjekter med finansiering fra Forskningsrådet fra 2004. Statistikken er fordelt på blant annet tema, år, geografi og organisasjon. Prosjektbanken gir også detaljert informasjon om de enkelte prosjektene.

...eller se sammendrag og annen informasjon om prosjektene i utvalget ditt

Alle porteføljestyrer

En god beskrivelse av denne siden for søkemotoroptimalisering

Forside

Hvordan tildelingene fordeler seg på institusjoner, fylker, fagområder o.l....

Her er noen eksempler på søk du kan gjøre i Prosjektbanken

Alle langtidsplanmål

Veiledning: Hvordan bruke Prosjektbanken.no

Om Fritekstsøk

Ingen populærvitenskapelig framstilling tilgjengelig


Prosjektet med prosjektnummer {{project number}} ble ikke funnet

Teknisk beskrivelse

Oisann, her gikk noe galt. Kan du prøve å laste siden på nytt?  Dersom feilen vedvarer, vennligst kontakt oss.         

Se statistikk relatert til dette langtidsplanmålet

Se prosjekter relatert til dette langtidsplanmålet

knyttet til dette LTP-målet har blitt tildelt penger

har blitt tildelt til prosjekter knyttet til dette LTP-målet

har blitt tildelt til prosjekter knyttet til denne porteføljen

knyttet til denne porteføljen har blitt tildelt penger

Om Prosjektbanken

Nærings- og fiskerid

Diverse

Energidepartementet

Klima- og miljødepar

Kunnskapsdepartement

Landbruks- og matdep

Forsvarsdepartemente

Teknologi

Medisin og helsefag

Telemark

LTP3 Styrket konkurransekraft og innovasjonsevne

LTP3 Et kunnskapsintensivt næringsliv i hele landet

LTP3 Uttesting og kommersialisering av FoU

LTP3 Høy kvalitet og tilgjengelighet

LTP3 Rettede internasjonaliseringstiltak

LTP3 Muliggjørende og industrielle teknologier

LTP3 Nano-, bioteknologi og teknologikonvergens

UoH-sektor

Instituttsektor

Næringsliv

Helseforetak

Offentlig sektor

Øvrige

Ukjent Sektor

Utlandet

ukjent

Portefølje Forskningssystemet

Portefølje Helse

Portefølje Innovasjon

Portefølje Muliggjørende teknologier

Nettverkstiltak

Frittstående prosjekter

Sverige

Koordinerings- og støtteaktivitet

Internasjonale utlysninger

Internasjonalisering

Anvendt forskning

Politikk- og forvaltningsområder

Artikkel 185 (ny fra 2014)

Bioteknologi

Bransjer og næringer

FNs Bærekraftsmål

Utviklingsarbeid

Verifisering, pilotering, demonstrasjon (ny fra 2014)

Limb wounds in horses are common, however healing is exceedingly slow and fraught with complications. Contrary to body wounds, limb wounds demonstrate only a small amount of wound contraction. The specialist procedure of applying split-thickness skin grafts to limb wounds stimulates wound contraction by unknown mechanisms. The objective of this project is to identify those mechanisms to develop a treatment strategy for equine limb wounds for use in general  practice. Limb wounds are severely impacting animal welfare due to an extended healing/treatment duration, and the risk of euthanasia due to a poor functional outcome. By stimulating wound contraction, healing time will be reduced, and the functional outcome improved, directly benefitting the welfare of wounded horse and reducing treatment cost for the owner. Aim: To identify dermal components stimulating wound contraction, and to develop this knowledge into future state-of-the-art treatment of equine limb wounds for use in general practice. Hypotheses: i) Application of dermal fractions to collagen gels seeded with equine fibroblasts will increase gel contraction in vitro; ii) Application of dermal fractions to experimental limb wounds in vivo, will increase wound contraction resulting in a faster healing time versus wounds treated by conventional methods. Methods: i) The contractile effect of different dermal components will be assessed in a collagen gel/ fibroblast model; ii) Identified dermal components will be tested in a standardized experimental limb wound model in vivo (n=5). Ultimately, results from this project are expected to improve wound treatment in horses, directly impacting animal welfare by reducing healing time and improving the functional outcome of wounded horses. This will also directly benefit horse owners and caretakers and making veterinarians able to offer better treatment solutions.

HESTEFORSK - Raskere og bedre sårheling hos hest med autologe hudkomponenter

The goal of the Bilingual Experiences, Cognitive Ageing and underlying Mechanisms (BECAME) project is to examine the functional neuroplastic mechanisms underlying mitigatory effects of bilingual experience on age-related cognitive decline. While evidence is available for structural brain changes supporting bilingualism-induced effects on cognitive aging (CA), functional mechanisms underlying such effects are not yet well understood. BECAME aims to fill this gap by investigating the trajectory of bilingualism-induced functional neuroplasticity across the adult lifespan (ages 18-85), crucially adopting an individual differences approach related to measurable degree of bilingual engagement. Importantly, although such benefits are thought to be rooted early in the lifespan, evidence for the timeframe and conditions of their early emergence is scarce. The choice of including the whole adult lifespan allows us to investigate these mechanisms and their emergence more directly from a lifespan perspective. I combine behavioral testing with brain recordings via electroencephalography (EEG). EEG is widely used in cognitive neuroscience to assess brain activity and the degree of communication between brain regions (functional connectivity) in response to stimuli and at rest. Combining behavioral and EEG modalities will allow me to test bilingualism’s effect on functional connectivity, as well as its consequences for functional efficiency, the minimum required neural activation to successfully perform a task. This will enable a detailed, evidence-based account of the protective effects observed in older-aged bilinguals, and how they are built from earlier life stages. By illuminating the relationship between multilingualism and resulting neurocognitive adaptations, BECAME will enable to capitalize on it as a health initiative, with manifold societal implications and the potential to be translated into actionable policies exploiting multilingualism to ameliorate effects of CA.

Bilingual Experiences, Cognitive Ageing and underlying Mechanisms

Hovedmålet med kreftbehandling er å eliminere kreftceller og dette er tradisjonelt oppnådd ved kirurgi, bruk av giftige medikamenter (cellegift) og stråling. En ny og betydningsfull tilnærming til kreftbehandling kalt immunterapi, har derimot fått mye oppmerksomhet det siste tiåret; Her forsøker leger og forskere å utnytte immunsystemet vårt for å målrettet  ødelegge kreftceller. En nøkkelaktør i denne banebrytende tilnærmingen er en gruppe «drapsmenn» i immunsystemet kjent som cytotoxiske T-lymfocytter (CTL-er). Disse cellene har en bemerkelsesverdig evne til å oppdage kreftceller ved å gjenkjenne unormale molekyler på overflaten av kreftcellene - molekyler som friske celler ikke har. Når CTL-er gjenkjenner kreftcellene ødelegger de dem ved å frigjøre giftige molekyler som initierer kreftcellenes selvdestruksjon. 
 
Selv om betydelige innsats har blitt dedikert til å forstå hvordan CTL-er aktiveres og hvordan de gjenkjenner kreftceller, vet vi mindre om de påfølgende hendelsene inne i kreftcellene som fører til deres død. Fra før vet vi at CTL-er kan initiere to forskjellige typer celledød i kreft: den første, kalt apoptose, er en stille og ordnet prosess der kreftcellene krymper og brytes opp uten å varsle immunsystemet; den andre, kalt pyroptose, er en mer dramatisk prosess som involverer dannelse av åpninger i cellemembranen, noe som fører til at cellene svulmer opp og sprekker. Under denne cellebristen blir innholdet inne i cellene frigitt i omgivelsene, og dette kan fungere som 'faretegn' som kan stimulere en sterkere immunrespons mot kreftcellene. Betydningen av denne cellebristen for å forsterke anti-tumorresponsene vil bli undersøkt i dette prosjektet. 
 
Videre er vi fascinert av muligheten for å avdekke ytterligere, ennå ukjente, former for celledød indusert av CTL-er. Utforsking av disse dødsrelaterte prosessene i kreftcellene kan potensielt øke effektiviteten av immunterapi og bidra betydelig i den pågående kampen mot kreft.

The primary goal of most cancer therapies is to induce cancer cell death. Immunotherapy relies on the cytotoxic activity of lymphocytes such as natural killer cells (NKs) and cytotoxic T lymphocytes (CTLs) to achieve this. While a significant amount of research in immunotherapy focuses on the events within cytotoxic lymphocytes or at the interface between cytotoxic lymphocytes and cancer cells, less is known about the molecular mechanisms that orchestrate cancer cell death, particularly in the case of CTL-mediated death.
CTLs are known to induce two types of cell death in cancer: non-inflammatory apoptosis and proinflammatory pyroptosis. Pyroptotic cancer cells release proinflammatory signals that attract immune cells to the tumor site, thereby enhancing the anti-tumor response. Cell lysis is a common outcome of pyroptotic cell death. It is unclear whether lysis can be decoupled from pyroptosis in cancer cells and whether the proinflammatory properties of pyroptotic cancer cell death depend on lysis. Moreover, it remains unknown whether CTLs can induce other forms of cell death in cancer, apart from apoptosis and pyroptosis.
Studying the mechanisms of CTL-mediated cancer cell death is challenging because CTLs selectively target cells expressing specific antigens. However, given the critical role of CTLs in immunotherapy, it is essential to deepen our understanding of CTL-induced cancer cell death.
This project aims to develop novel methodologies to investigate the death mechanisms that are initiated by CTLs. In addition, we will identify new pathways and mediators involved in CTL-induced cancer cell death. Furthermore, we will assess the contribution of proinflammatory cell death and lysis in promoting anti-tumor responses in vivo. Overall, this research will improve our knowledge of the molecular mechanisms of CTL-mediated cancer cell death and potentially reveal novel targets to enhance the efficacy of cancer immunotherapy.

T-cell-mediated proinflammatory cell death and lysis in cancer

En av de vanligste, men minst studerte, utfordringene med å bli eldre er problemer med å kommunisere. Mange eldre sliter spesielt med pragmatiske ferdigheter, som å forstå undertekst, eller tilpasse det de sier til personen de snakker med. 

La oss si at en lege må gi en alvorlig beskjed til en pasient. For å gjøre det litt lettere å takle, bruker legen vagere språk, som "kanskje" i stedet for "sannsynligvis". Mens yngre voksne ofte tar hensyn til høflighetsstrategier i måten de tolker det som blir sagt på, har eldre ofte vanskelig for å forstå når noen snakker indirekte. Mange eldre voksne har vanskelig for å forstå ikke-bokstavelig språk og kan misforstå alvorlighetsgraden av diagnosen. Dette kan påvirke beslutningen deres om behandling, noe som kan føre til utilsiktede konsekvenser. 

Siden god kommunikasjon er viktig både i viktige medisinske samtaler og i hverdagen, er det viktig at vi finner ut hva som gjør at eldre kan ha vansker med å forstå og bli forstått. RESILIENCE skal hjelpe til med denne utfordringen ved å samle data om praktiske, kognitive og språklige ferdigheter hos voksne i alderen 18-90 år over tid. Dette vil gi oss en stor mengde data om pragmatiske, kognitive og språk ferdigheter og gjøre det tilgjengelig for forskning. Med denne dataen som grunnlag har vi følgende mål: 

• Forstå hvordan praktiske evner endrer seg generelt gjennom voksenlivet. 
• Finne ut hvilke mekanismer som påvirker pragmatiske evner på forskjellige tidspunkter i livet.
 • Utvikle en teoretisk modell som forklarer hvordan pragmatiske ferdigheter endrer seg med alderen.
 • Lage algoritmer som kan forutsi hvordan pragmatiske evner vil utvikle seg for enkeltpersoner i årene som kommer. 
• Utvikle og teste et verktøy som kan måle pragmatisk helse (både pragmatiske ferdigheter og deres underliggende mekanismer), noe som kan åpne  for å iverksette tiltak. 

Dette vil gi oss muligheten til å forstå bedre hvordan folk kan utvikle pragmatisk resiliens gjennom livsløpet.

A cornerstone of human communication is our reliance on pragmatic skills to guide linguistic interactions (e.g., reasoning about others' mental states to bridge the gap between what is said and intended in conversation). However these skills are highly sensitive to age-related decline, leading to miscommunication and uninformed decision making in the older adult population. This raises an important question, one which has puzzled linguistics and psychologists for decades: if pragmatic competence is fundamental to communication, why do individuals vary so much in this capacity? 

Traditionally, psychologists have approached pragmatic competence from a cognitive angle, reasoning that individual differences in executive functions (i.e., the cognitive skills associated with goal-directed actions) are what underlie effective pragmatic behavior. In a similar vein, language scientists have taken a linguistic approach, reasoning that one’s language background (e.g., the frequency with which individuals shift between languages) shapes pragmatic skills by enhancing sensitivity to the communicative context. This focus on either cognitive or linguistic influences has resulted in two expansive yet disparate areas of research.

RESILIENCE will unite these disciplines to pursue a longstanding debate on what underlies pragmatic resilience and decline using a large-scale, interdisciplinary and longitudinal approach. By gathering data on adults' (ages 18-90) pragmatic, cognitive and language skills over multiple time points, we will develop a comprehensive theoretical model that explains how cognitive and linguistic systems interact to shape pragmatic competence as we age, and create algorithms that predict the trajectory of an individual’s pragmatic abilities in upcoming years. Based on these results we will design a multidimensional tool that detects the earliest signs of pragmatic deficits, leading to future interventions, allowing us to uncover the paths to pragmatic resilience.

Uncovering the paths to pragmatic resilience

Sink er et essensielt mikronæringsstoff som kreves for funksjonen til hundrevis av proteiner involvert i et bredt spekter av biologiske prosesser. Etter inntak av sink fra kosten reguleres nivåene i kroppen nøye gjennom absorpsjon, sekresjon og ekskresjon via spesialiserte proteiner, såkalte sinktransportører, i tarmen. Enhver ubalanse er skadelig for menneskers helse, spesielt er tarmen følsom for sinkfluktuasjoner, hvilket påvirker tarmbarrieren og kan føre til inflammatoriske sykdommer og kreft i tarmen. 
På molekylært nivå er de presise mekanismene som styrer funksjonen til de ulike sinktransportørene fortsatt uklare. Hos mennesker finnes det over tjue slike proteiner, og de fleste inneholder områder rike på aminosyren histidin. Disse histidinene mistenkes å spille en avgjørende rolle i å binde sink. Nylig oppdaget vi et enzym som modifiserer disse områdene ved å sette metylgrupper på histidin, og viste at metylerte histidiner har en lavere affinitet for sink. Dette prosjektet har som mål å identifisere nye mekanismer som regulerer sinknivåer gjennom histidinmetylering av sinktransportører, å utvikle forskningsverktøy for effektiv studie av histidinmetylering, og å legge grunnlaget for nye behandlinger av tarmsykdommer.

The delicate balance of zinc levels in the body is essential for human health. Zinc is absorbed and excreted via intestinal zinc transporter proteins, and perturbations of this process are associated with pathologies, including inflammatory diseases and cancers of the bowel. The precise molecular mechanisms regulating zinc transport, however, remain a major knowledge gap. Based on the recent discovery of an enzyme methylating histidine residues in zinc transporters, and drawing on preliminary findings which demonstrate reduced affinity of methylated histidines to zinc, this project aims to identify novel mechanisms regulating zinc homeostasis through histidine methylation. We will examine the regulation and effect of histidine methylation on zinc transport in intestinal cell culture and organoids, and examine how knockout of the methylhistidine-generating enzyme affects the integrity and pathology of the intestinal tract in mouse models. In addition, we will identify reader proteins specifically recognizing methylhistidines and develop anti-methylhistidine antibodies and inhibitors to use as tools for detection, enrichment, and inhibition of histidine methylation. Such tools are urgently needed by the international research community, as none are currently available commercially. Overall, this project will lead to great advances in the field of protein regulation, and may uncover novel mechanisms in intestinal zinc transport and pathology.

Zinc transport regulation through histidine methylation

Noen av oss tåler stressende livshendelser godt. Andre derimot utvikler vedvarende fysiske og psykiske plager som følger av stress. Hvor godt vi håndterer stress avhenger av et komplekst samspill mellom miljøfaktorer, sosiale forhold, biologisk sårbarhet og indre motstandskraft. Forskning på stressreaksjonene til dyr og pasientgrupper som til vanlig lever under mye stress viser at en gruppe signalstoffer i kroppen som aktiverer det samme hjernesystemet som cannabis – endocannabinoidene – kan begrense styrken på stressreaksjoner og bidra til at man raskere kommer seg til hektene. I dette prosjektet skal vi undersøke hvordan mestring av stress på kort og lang sikt henger sammen med nivåer av endocannabinoider i kroppen for å forstå hvorfor noen personer er mer motstandsdyktige mot stress enn andre. I den ene studien følger vi pasienter som skal gjennomgå en stressende, men veldig vanlig, situasjon: kirurgi. Her måler vi pasientenes opplevelse av stress, samt mentale og fysiske helse, fra tiden før til to år etter operasjonen og undersøker hvordan dette henger sammen med nivåene deres av endocannabinoider og andre stresshormoner. I den andre studien bruker vi data fra et eksperiment hvor deltakerne har blitt utsatt for psykososialt stress til å undersøke om endocannabinoidnivået deres påvirker hvordan de reagerer på stress, og om stresset i seg selv kan påvirke kroppens produksjon av endocannabinoider. Til syvende og sist er målet med studien å vurdere hvorvidt målinger av endocannabinoidnivåer kan brukes til å forebygge helseplager og til å evaluere behovet for økt oppfølging etter alvorlig stressende påkjenninger i livet.

In the face of major life stressors, some individuals cope well whereas others develop ill health and long-term adverse outcomes. Predicting who needs additional support in response to major life stressors is essential for targeted prevention and more efficient allocation of resources. The endocannabinoid system is emerging as a promising target for understanding vulnerability and resilience to stress. This system appears to buffer stress in two ways: by limiting the magnitude of the stress response, and by facilitating recovery after a stressful event. While the early findings are intriguing, they mainly stem from studies in rodents and small clinical groups with high stress burden. What role endocannabinoids have more globally for human resilience, health and well-being remains elusive. 

In this project we address this gap by leveraging comprehensive experimental and clinical data on two potent stress models: psychosocial stress and surgery. Drawing on these unique datasets, which combine experimental control with ecological validity, we will decipher how endocannabinoid levels influence people’s stress response and recovery across minutes, days, weeks and years. The project represents a novel directional shift for endocannabinoid research and will (i) determine the value of endocannabinoid levels as a biomarker to predict outcomes after surgery, (ii) quantify sex differences, (iii) assess endocannabinoid interplay with opioid analgesics, sex hormones and other stress markers (iv) spearhead open and reproducible science practices in endocannabinoid research, and (v) make this fine-grained and novel data available through an interactive web application. 

This project represents an ambitious effort to understand endocannabinoids’ role in stress resilience and will determine the value of endocannabinoids as a predictive biomarker and potential target for individualized treatment.

Deciphering endocannabinoid stress buffering in humans: 
Mechanistic and clinical investigations

WHeelchair Activity Monitoring project (WHAM)

Wheelchair users (WCU) are three to five times more inactive than the general population, leading to a high risk of developing preventable secondary conditions. Although physical activity (PA) guidelines have been specifically developed for WCU, we lack systematic approaches to implement them in practice, as well as valid algorithms to monitor PA change in WCU through sensor-based solutions. Accordingly, the overall scientific aim of the WHeelchair Activity Monitoring project (WHAM) is to advance PA research and practice in WCU by developing valid digital markers for monitoring of and providing feedback on PA, paving the way for implementation and intervention. I will accomplish this through combining the complementary research fields of 1) behavioural intervention studies focusing on increasing PA in WCU (core competence University of British Columbia, UBC; outgoing phase) and 2) sensor-based PA monitoring (core competence Norwegian University of Science and Technology, NTNU; returning phase – consolidated by non-academic placement at Maastricht Instruments, which develop research prototypes including PA monitors). WHAM’s scientific aim is achieved through three objectives: 1) Measure the effect of a pragmatic exercise intervention trial on self-reported physical activity levels and cardio-respiratory fitness, 2) Develop valid algorithms for tracking PA markers in WCU, and 3) Co-create a framework that outlines how PA can be conjointly monitored and provided feedback on in WCU. This fellowship will enable me to become established as an internationally recognized researcher in the field of “physical activity and disability”, while bringing together ongoing national disjointed research activities in this field. Altogether, my overall ambition is to contribute to reducing inequalities in daily-life participation among WCU compared to the rest of the population.

BOLD MINDS aspires to enhance the understanding of vulnerability factors underlying the emergence of borderline personality disorder (BPD), with an ultimate aim of increasing the potential for young individuals to receive early, evidence-based help when their mental health is at risk. BOLD MINDS will achieve this by investigating whether disruptions in two aspects of autobiographical memory (AM), narrative identity (NI) and involuntary AM (IAM), are associated with BPD features and problem behaviours in adolescents concurrently and over time. In doing so, BOLD MINDS will strengthen the understanding of mechanisms underlying the emergence of BPD in adolescence and lay a groundwork for developing evidence-based early interventions for BPD. While currently limited, the study of AM in this field is essential for two reasons. Firstly, because the aspects of AM under investigation, NI and IAM, are known to be involved in identity formation and emotion regulation which represent two key psychological processes that are disrupted in adults with BPD and are linked to problem behaviours such as self-harm and suicidality. Secondly, because promising research is emerging on the use of AM targets in the treatment of emotional disorder in adults, and provides a strong model for future treatment development with vulnerable adolescents. In addition, this timely research program aligns with calls from international organizations to prioritize early interventions to promote adolescent mental health. BOLD MINDS will adopt and adapt state-of-the-art ecological momentary assessment and analytical techniques and work at the crossroads of clinical and cognitive psychological perspectives, allowing for a multidimensional approach to understanding BPD vulnerability. Training-through-research and formalized training of the experienced researcher will prepare her for a permanent academic position and the founding of her own research lab specializing in AM and early interventions for BPD.

Borderline Personality Disorder: Memory and Identity in Adolescence

Per- og polyfluorerte stoffer (PFAS) er en stor gruppe menneskeskapte kjemikalier med høyt fluorinnhold som antas å ha negative helseeffekter. Kilder til PFAS kan være produksjon av vann-, varme- og flekkbestandige produkter og disse kjemikaliene er en del av hverdagen vår. PFAS påvirkning av biologiske systemer er ikke fullstendig forstått. Noen PFAS er antatt å øke risikoen for å utvikling av ikke-alkoholisk fettleversykdom (NAFLD) og øke risikoen for diabetes. 

For å forstå hvordan PFAS påvirker organene våre ønsker vi å bruke små laboratoriedyrkede organmodeller, kalt organoider. Disse miniatyrorganene kan dyrkes fra menneskelige stamceller og tilbyr et kontrollert miljø for å studere hvordan PFAS påvirker f.eks lever og bukspyttkjertelen vår, uten bruk av dyreforsøk.

For å studere helseeffekter må vi kunne måle nivået av biomolekyler som fettstoffer i leveren og hormoner i bukspyttkjertelen. Til dette trenger vi å utvikle analytiske verktøy for å måle effektene. Først vil vi bekrefte at når leverorganoidene eksponeres for enkelte PFAS-forbindelser utvikles det NAFLD-lignende sykdom ved å sammenligne den biokjemiske profilen (proteiner og metabolitter) til organoider av lever med PFAS-eksponerte organoider. Deretter vil vi utvide den analytiske verktøykassen for å undersøke hvilke metabolske veier som påvirkes, og om effekten er den samme i NAFLD-induserte og PFAS-eksponerte organoider. Vi vil også eksponere insulinproduserende bukspyttkjertelorganoider for PFAS for å undersøke effekten av PFAS på hormonproduksjon. Når effektene av PFAS-eksponering på lever- og bukspyttkjertel-organoider er etablert, vil organoidene bli samkultivert i en chip, og effektene av PFAS-eksponering vil bli undersøkt og sammenlignet med individuelle organoider.

Persistent organic pollutants (POPs) are believed to contribute to metabolic diseases, such as non-alcoholic fatty liver disease (NAFLD) and type 1 diabetes. HE-POP aims to investigate the effects of per- and polyfluoroalkyl compounds (PFAS), a type of POPs), on organ function in a controlled environment.

Organoids are multicellular laboratory-grown miniature organs, that are grown from stem cells. HE-POP will use organoids to examine how PFAS affects our organs and develop cutting-edge bioanalytical tools and methodology to measure these effects using liquid chromatography-mass spectrometry. HE-POP hypothesizes that PFAS negatively affects organ function, as evidenced by changes in hormone and lipid levels characteristic of NAFLD and type 1 diabetes. 

Organoids offer a controlled environment to study the effects of PFAS on the liver and pancreas, without the use of animal models. HE-POP aims to gain evidence of the negative effects of PFAS on organ function through controlled experiments on organoids and aid in understanding the biological mechanisms underlying NAFLD and type 1 diabetes.

HE-POP has fundaments in UN sustainable development goals, specifically #3, #12, and #14/15, seeking an understanding of diseases with worldwide prevalence, and understanding how POPs affect our life and surroundings and help enable the right regulatory actions and replacement chemicals.

HE-POP: Studying the Health Effects of Persistent Organic Pollutants, Using Mass Spectrometry, Organoids, and Organ-On-A-Chip

Dette prosjektet, kalt Hukommelse for musikk, fokuserer på det økende antallet mennesker over hele verden som lever med demens, spesielt Alzheimer's sykdom (AD). AD starter typisk med hukommelsesproblemer og påvirker etter hvert daglige aktiviteter. Aktive musikkintervensjoner, spesielt sang, har vist positive effekter på humør, atferd og livskvalitet for personer med demens, men deres innvirkning på kognisjon er ikke godt forstått. Prosjektet har som mål å fylle dette kunnskapsgapet ved å studere effektene av å lære nye sanger på kognitiv, atferdsmessig og hjernemessig funksjon.

Studien vil omfatte hjemmeboende voksne over 65 år med AD fra Argentina, Østerrike og Norge. Deltakerne vil gjennomgå 5 måneder med intensiv musikalsk opplæring (to ganger i uken) og 5 måneder med minimal opplæring (en gang i måneden) i tilfeldig rekkefølge, med en to måneders pause imellom. Intervensjonene inkluderer å lære nye sanger med en personlig musikklærer. Generell kognisjon vil bli målt ved bruk av Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog), og hukommelse for musikk vil bli vurdert gjennom ulike metoder, inkludert atferdsoppgaver og hjerneaktivitet (EEG). Humør vil også bli evaluert i hver økt.

Målet er å inkludere 113 deltakere for å sikre pålitelig påvisning av meningsfulle effekter. Studien vil utforske hvordan humør og hukommelse for musikk bidrar til endringer i kognitive evner, og om disse effektene varierer basert på faktorer som kjønn, alder, AD-stadium, eller tidligere musikalsk opplæring og generell utdanning. Prosjektet vektlegger samarbeid mellom forskere, tjenesteytere og brukere for å sikre studiens relevans og anvendelighet.

The number of people living with dementia is increasing and is high in low, middle, and high-income countries. Alzheimer’s disease (AD), the most common type of dementia, manifests itself initially with cognitive impairment in memory domains, and later affects all activities of daily living. Active music interventions, particularly singing, can help to improve mood, behaviour problems, and quality of life. Too little is known about their effects on cognition, although some promising studies exist. The M4M project aims to fill this gap by measuring effects of learning new songs on clinical, behavioural and brain functioning. Specifically, M4M aims to examine changes in general cognitive functioning and memory for music in non-musician adults with AD undergoing intensive individual musical training based on singing novel songs, compared to minimal training.
        Home-dwelling adults with AD, 65 years or older, in 3 countries (Argentina, Austria, Norway), will receive 5 months of intensive intervention (2x/week) and 5 months of minimal intervention (1x/month), in random order, with a 2-month break in between. Interventions will entail learning new songs with an individual music teacher. At the end of each intervention period, general cognition will be measured with the Alzheimer's Disease Assessment Scale – Cognitive (ADAS-cog) by a person who is unaware of the intervention received. Memory for music will be tested with observations, behavioural tasks, and brain responses (EEG). Mood will be assessed in each session. We aim to include 113 participants; this will help us to reliably detect clinically meaningful effects. We will also examine how mood and memory for music lead to changes in cognitive abilities, and whether effects depend on sex, age, AD stage, or previous musical training or general education. M4M will be conducted in close collaboration between academic researchers, service providers, and service users to ensure relevance and applicability.

Memory for Music: Effects of individual intensive musical training based on singing in non-musicians with Alzheimer’s disease

Midlene fra FUNN-3-Tilskudd til ulønnet FoU-innsats fordelt på år

Midlene fra FUNN-3-Tilskudd til ulønnet FoU-innsats fordelt på fylker

Midlene fra FUNN-3-Tilskudd til ulønnet FoU-innsats fordelt på fagområde

Prosjektansvarlig

28139 Modul for markedsundersøkelse

This PES application is to financially support a high quality application for the EIC Pathfinder Challenge: Towards the Healthcare Continuum: technologies to support a radical shift from episodic to continuous healthcare. This is further developmental work from our WomenTech EU project, complementing our drug development Eurostars project.

We believe this Pathfinder Challenge is highly suitable for our a-DOC medical home device. This is an accurate, rapid, compact and affordable system for consumers to have at home and measure their autoimmune disease activity using biometric data collected non-invasively, an approach that is highly novel and builds upon the ground-breaking scientific research. The data collected at home would be sent to an app on the owners smartphone showing how the each biometric is trending over time. 

We aim to develop this device for life-long monitoring of autoimmune diseases predicting flares and increases in disease activity early so that patients and healthcare providers can be warned of worsening disease activity and treated quickly. The end objective is proof of concept minimal viable product, and preliminary data from clinical studies to suggest adequate safety and performance of the device paying attention to minimizing false positives. 

No device exists today to monitor autoimmune disease activity rapidly or accurately at home, giving results in a simple and meaningful way (i.e., digitally in an app). The only exception is  glucose monitoring for diabetics which is a very different application.

A-Doc, Smart Personalised Biometric Monitor

This PES application is to financially support a high quality EU application to Women TechEU for companies with female founders whose industry involves deep tech innovation. We believe this Women TechEU call would be highly suitable and complement our ambition to create, market and sell a disruptive health technology that we are developing; ´Smart Personalised Aging Sensors`. This is an aesthetically appealing elegant device for consumers to have at home and measure their rate of aging (whether this is healthy aging or not) using biometric data (from saliva). The data collected at home would be sent to an app on the owners smartphone showing how the rate of aging is trending over time. 

The Women TechEU call would help us in our aim of eventually reaching the global market. This would be through increasing our network globally contributing to increased scalability of the business. The financial support for project activities, mentoring and networking opportunities provided from this call would aid in our ultimate ambition to be a world-renowned company which exploits the endocrine-immune interface for better health. This is in the form of pharmaceuticals (we have a separate drug development programme funded by Eurostars for this), as well as disruptive technologies such as the product outlined above, a device to measure aging and wellness at home. Our critical challenges are financing and resources.

Background of technology: Today, we can draw conclusions as to why some people have ´younger`biological age than others. Its generally all the things you would think: not smoking, no excess alcohol, exercising regularly etc. But in the future people would be able to use our product to track their good or bad health habits. Our product uses a unique aging marker (based on 15 years of our research) that has never been considered in the field before (further described in the project description).

Smart Personalised Aging Sensor (Elevating the scalability potential of European Business call)

Målet vårt er å tilby en revolusjonerende behandling for 600 millioner mennesker over hele verden som lider av autoimmune sykdommer. Nåværende behandlinger har moderat effekt og kan gi alvorlige bivirkninger. Vi tar sikte på å forbedre pasientens medisinske tilstand i større grad enn dagens medisiner og med færre bivirkninger, først med revmatoid artritt (RA). RA er en vanlig autoimmun sykdom som forårsaker alvorlige smerter og ledddeformiteter. I tillegg til de enorme fordelene for pasienter, kan vi bidra til å redusere de direkte og indirekte kostnadene ved RA. Den totale kostnaden for RA i Europa er 45,3 milliarder Euro. Vår tilnærming forventes å være mer kostnadseffektiv enn eksisterende biologiske medikamenter og kan spare rundt 400 millioner Euro per år på RA-legemidler i Europa, mens forbedret helse til pasientene kan redusere samfunnskostnadene med 395 millioner Euro.

E!114520 ACTION has been approved as a Eurostars labelled project by the EUREKA association. The project consortium,  is focussed on development of drugs for the treatment of autoimmune diseases. The novel drug will target the endocrine-immune interphase and the strong relationship between the level of hormones and symptom severity of autoimmune diseases such as rheumatoid arthritis . The goal of the project is to develop drugs that have a more upstream role than current drugs in the deleterious cascade of events leading to inflammation and joint damage. The project, with a total budget of 1.6 million Euros and duration of 36 months, will be focused on evaluation of the effects of the developed drug candidates  in autoimmunity in preclinical studies. By combining niched and specific competences of the consortium members we aim to deliver an IND approved drug ready for first-in-human trials post-project.

E! 114520 ACTION: A pioneering strategy to treat autoimmune diseases

Kaass Discovery, headed by Anita Kaass, is a drug development company awarded best regional start up in 2018 at the regional Innovation Norway´s start up conference. 
This project aims to deliver a unique therapy for autoimmune disease, which affects 600 million people globally. Our first aim will be to focus on the autoimmune disease rheumatoid arthritis (RA). Today’s biologic drugs often have unacceptable side effects and only 60% efficacy rates.
Dr Kåss was intrigued by the improvements in disease activity in several autoimmune diseases during pregnancy and worsening postpartum. Therefore in 2006 she mapped out which hormones were closely related to immune markers. She discovered that it was beneficial to decrease the master hormone of the reproductive hormone, gonadotropin-releasing hormone (GnRH), initiating the first clinical trial of GnRH antagonists in RA, with promising results. GnRH not only regulates the reproductive hormone cells, but also acts on immune cells to regulate inflammatory reactions. However these drugs have the side effect of castration.
Our second-generation refined drugs appear to be strongly anti-inflammatory and target only the peripheral GnRH receptor therefore having no reproductive side-effects. We have filed in our patent application 11,500 new peptides that have a range of similar anti-inflammatory activities, and selected the 14 most promising candidates. However this project needs to validate this potential in  further in vitro and in vivo safety and efficacy studies, with the eventual aim of out-licensing the drug.

A pioneering strategy to treat autoimmune diseases that enables patients to live symptom free

Kaass Discovery, headed by Dr. Anita Kåss, is a drug development company, recently awarded best start up in 2018 at Innovation Norway´s regional startup conference. 

This project will deliver a unique therapy for autoimmune disease, which affects 600 million people globally. Our first aim will be to focus on the autoimmune disease rheumatoid arthritis (RA). Today’s biologic drugs often have unacceptable side effects and only 60% efficacy rates.   

Dr Kåss was intrigued by the improvements in disease activity in several autoimmune diseases during pregnancy and worsening postpartum. Therefore in 2006 she mapped out which hormones were closely related to immune markers. She discovered that it was beneficial to decrease the master hormone of the reproductive hormone, gonadotropin-releasing hormone (GnRH), initiating the first trial of GnRH antagonists in RA, with promising results. GnRH not only regulates the reproductive hormone cells, but also acts on immune cells to regulate inflammatory reactions. However these drugs have the side effect of castration.

Our second-generation refined drugs appear to be strongly anti-inflammatory and target only the peripheral GnRH receptor therefore having no reproductive side-effects. We have filed in our patent application 11,500 new peptides that have a range of similar anti-inflammatory activities, and selected the 14 most promising candidates. However this project needs to validate this potential from in vitro and in vivo safety and efficacy studies, and finally the first in human phase I trial, with the aim of out-licensing the drug.     

Our critical challenges are finances and resources. Kaass Discovery is currently a new company founded in 2017 with limited capital. However, we own IPR with substantial potential.  We have exclusive agreements with one of the largest service for fee laboratories worldwide, Charles River Laboratories. Kaass Discovery will also need to employ excellent researchers and project developers.

0 antall prosjekter

PES-HORISONT-EU-PES Horisont Europa

A-Doc, Smart Personalised Biometric Monitor

Tildelt: kr 0,35 mill.

Prosjektperiode: 2022-2023

Sted: Telemark

PES-HORISONT-EU-PES Horisont Europa

Smart Personalised Aging Sensor (Elevating the scalability potential of European Business call)

Tildelt: kr 49 999

Prosjektperiode: 2021-2022

Sted: Telemark

EUROSTARS-EUROSTARS

E! 114520 ACTION: A pioneering strategy to treat autoimmune diseases

Tildelt: kr 5,6 mill.

Prosjektperiode: 2020-2024

Sted: Telemark

PES2020-Prosj.etabl.støtte H2020

A pioneering strategy to treat autoimmune diseases that enables patients to live symptom free

Tildelt: kr 99 999

Prosjektperiode: 2019-2020

Sted: Telemark

PES2020-Prosj.etabl.støtte H2020

PES 2020 for SME Phase II: A pioneering strategy to treat autoimmune diseases that enables patients to live symptom free

Tildelt: kr 74 999

Prosjektperiode: 2019-2019

Sted: Telemark